Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2020
Historique:
received: 21 08 2020
accepted: 03 11 2020
entrez: 1 1 2021
pubmed: 2 1 2021
medline: 4 6 2021
Statut: epublish

Résumé

Non-Alcoholic Steatohepatitis (NASH) is the progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD), the main cause of chronic liver complications. The development of NASH is the consequence of aberrant activation of hepatic conventional immune, parenchymal, and endothelial cells in response to inflammatory mediators from the liver, adipose tissue, and gut. Hepatocytes, Kupffer cells and liver sinusoidal endothelial cells contribute to the significant accumulation of bone-marrow derived-macrophages and neutrophils in the liver, a hallmark of NASH. The aberrant activation of these immune cells elicits harmful inflammation and liver injury, leading to NASH progression. In this review, we highlight the processes triggering the recruitment and/or activation of hepatic innate immune cells, with a focus on macrophages, neutrophils, and innate lymphoid cells as well as the contribution of hepatocytes and endothelial cells in driving liver inflammation/fibrosis. On-going studies and preliminary results from global and specific therapeutic strategies to manage this NASH-related inflammation will also be discussed.

Identifiants

pubmed: 33384662
doi: 10.3389/fendo.2020.597648
pmc: PMC7771356
doi:

Substances chimiques

Inflammation Mediators 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

597648

Informations de copyright

Copyright © 2020 Luci, Bourinet, Leclère, Anty and Gual.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Immunol. 2019 May 28;10:1192
pubmed: 31191550
Cell Mol Gastroenterol Hepatol. 2016 May 05;2(5):584-604
pubmed: 28090564
J Biol Chem. 2013 Apr 26;288(17):11761-70
pubmed: 23460643
Endocrine. 2017 Jul;57(1):72-82
pubmed: 28508193
Immunity. 2016 Aug 16;45(2):428-41
pubmed: 27496734
Biochem Biophys Res Commun. 2019 Oct 22;518(4):691-697
pubmed: 31472960
Tumour Biol. 2014 Mar;35(3):2095-102
pubmed: 24092576
Curr Opin Immunol. 2019 Feb;56:82-93
pubmed: 30529190
Cell Metab. 2018 Jan 9;27(1):22-41
pubmed: 28867301
Gastroenterology. 2020 May;158(7):1865-1880.e1
pubmed: 32068025
Front Endocrinol (Lausanne). 2020 Apr 29;11:259
pubmed: 32411096
Gastroenterology. 2010 Apr;138(4):1346-56, 1356.e1-3
pubmed: 20060831
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
Nat Med. 2009 Aug;15(8):930-9
pubmed: 19633656
PLoS One. 2010 Oct 22;5(10):e13577
pubmed: 21042596
Adv Exp Med Biol. 2003;544:181-96
pubmed: 14713228
Sci Transl Med. 2016 May 18;8(339):339ra69
pubmed: 27194727
Hepatology. 2020 Jan;71(1):363-374
pubmed: 31230380
World J Hepatol. 2019 Feb 27;11(2):138-149
pubmed: 30820265
Liver Int. 2006 Sep;26(7):856-63
pubmed: 16911469
J Hepatol. 2015 Feb;62(2):412-20
pubmed: 25234945
Diabetes. 2015 Apr;64(4):1120-30
pubmed: 25315009
Nat Immunol. 2018 Dec;19(12):1330-1340
pubmed: 30420624
Gut. 2018 May;67(5):963-972
pubmed: 29367207
J Hepatol. 2018 Feb;68(2):268-279
pubmed: 29122391
Biochimie. 2017 May;136:65-74
pubmed: 27916647
J Hepatol. 2020 Mar;72(3):528-538
pubmed: 31726115
Hepatology. 2013 Dec;58(6):1941-52
pubmed: 23703580
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82
pubmed: 12629214
Front Immunol. 2019 Jun 04;10:1255
pubmed: 31214196
Nat Commun. 2016 Jan 27;7:10321
pubmed: 26813785
Lancet. 2019 Dec 14;394(10215):2184-2196
pubmed: 31813633
Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95
pubmed: 27432073
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Hepatology. 2009 Jul;50(1):185-97
pubmed: 19441102
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2009 Jul;50(1):261-74
pubmed: 19554540
Antioxid Redox Signal. 2015 Dec 1;23(16):1255-69
pubmed: 26058518
Hepatology. 2018 May;67(5):1754-1767
pubmed: 28833331
J Hepatol. 2014 May;60(5):1063-74
pubmed: 24412608
PLoS One. 2012;7(12):e52411
pubmed: 23285030
J Hepatol. 2019 Feb;70(2):249-259
pubmed: 30658726
Aliment Pharmacol Ther. 2010 Dec;32(11-12):1315-22
pubmed: 21050233
JHEP Rep. 2019 Feb 23;1(1):30-43
pubmed: 32149275
Front Immunol. 2019 Sep 11;10:2180
pubmed: 31572388
Diabetes. 2010 Feb;59(2):347-57
pubmed: 19934001
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
JHEP Rep. 2019 Jul 31;1(3):214-226
pubmed: 32039372
Biochem Pharmacol. 2014 Jun 15;89(4):503-14
pubmed: 24704474
Ann Intern Med. 2016 Sep 6;165(5):305-15
pubmed: 27322798
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2014 Dec;61(6):1365-75
pubmed: 25048951
Aliment Pharmacol Ther. 2012 Jan;35(1):66-75
pubmed: 22050199
Gut. 2020 Mar;69(3):551-563
pubmed: 31076404
Clin Gastroenterol Hepatol. 2015 Mar;13(3):561-568.e1
pubmed: 25218667
Diabetes. 2015 Mar;64(3):867-75
pubmed: 25294945
Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1143-1152
pubmed: 30261763
Nat Med. 2009 Aug;15(8):914-20
pubmed: 19633658
Hepatology. 2008 Feb;47(2):729-36
pubmed: 18167066
Sci Rep. 2019 May 16;9(1):7501
pubmed: 31097771
Cell Metab. 2008 Oct;8(4):301-9
pubmed: 18840360
Gastroenterology. 2014 Sep;147(3):577-594.e1
pubmed: 25066692
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
J Korean Med Sci. 2017 Jan;32(1):60-69
pubmed: 27914133
Hepatology. 2010 Feb;51(2):511-22
pubmed: 20054868
J Clin Invest. 2009 Jul;119(7):1858-70
pubmed: 19603542
Cell Metab. 2017 Mar 7;25(3):506-521
pubmed: 28273474
Hepatology. 2019 Sep;70(3):1026-1037
pubmed: 30653691
Gastroenterology. 2020 Oct;159(4):1471-1486.e12
pubmed: 32553762
Obes Rev. 2016 Jun;17(6):485-98
pubmed: 26948388
J Clin Transl Hepatol. 2015 Mar;3(1):9-16
pubmed: 26356325
J Hepatol. 2017 Aug;67(2):328-338
pubmed: 28323124
Cell Metab. 2016 Apr 12;23(4):685-98
pubmed: 27050305
Hepatology. 2016 Dec;64(6):2015-2027
pubmed: 27639192
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Gut. 2020 Aug;69(8):1483-1491
pubmed: 31900291
Liver Int. 2015 Mar;35(3):953-66
pubmed: 24750664
Front Physiol. 2016 Aug 19;7:344
pubmed: 27594839
PLoS One. 2014 Apr 15;9(4):e92843
pubmed: 24736628
Clin Gastroenterol Hepatol. 2019 May;17(6):1040-1060.e11
pubmed: 30326299
Gut. 2012 Mar;61(3):416-26
pubmed: 21813474
Gastroenterology. 2020 Apr;158(5):1334-1345.e5
pubmed: 31812510
J Clin Invest. 2010 Nov;120(11):4129-40
pubmed: 20978355
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Diabetes Res Clin Pract. 2015 Dec;110(3):e27-30
pubmed: 26458774
Hepatology. 2007 Jun;45(6):1366-74
pubmed: 17476695
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Am J Physiol Cell Physiol. 2017 Mar 1;312(3):C263-C273
pubmed: 27903585
Sci Rep. 2017 Mar 16;7:44612
pubmed: 28300213
J Hepatol. 2013 Mar;58(3):549-56
pubmed: 23142622
Liver Int. 2013 Nov;33(10):1549-56
pubmed: 23682724
Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):17-29
pubmed: 23347840
J Hepatol. 2020 May;72(5):816-827
pubmed: 31887369
World J Gastroenterol. 2014 Oct 21;20(39):14430-41
pubmed: 25339829
Cytokine. 2016 Jun;82:102-11
pubmed: 26868085
J Hepatol. 2020 Jul;73(1):26-39
pubmed: 32147362
Nature. 2014 Oct 9;514(7521):237-41
pubmed: 25119041
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159
pubmed: 30482910
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
J Cell Physiol. 2018 Aug;233(8):6224-6231
pubmed: 29336497
Hepatology. 2016 Mar;63(3):799-812
pubmed: 26662852
Hepatol Commun. 2018 Mar 07;2(5):529-545
pubmed: 29761169
Nat Med. 2017 Jun;23(6):742-752
pubmed: 28481357
Gastroenterology. 2020 Oct;159(4):1290-1301.e5
pubmed: 32553765
Clin Transl Immunology. 2016 Aug 19;5(8):e98
pubmed: 27588203
Biomed Res Int. 2014;2014:120179
pubmed: 25295245
J Hepatol. 2012 Dec;57(6):1305-11
pubmed: 22871499
Nature. 2007 Jun 28;447(7148):1116-20
pubmed: 17515919
Hepatology. 2014 Jan;59(1):130-42
pubmed: 23832548
Nat Immunol. 2015 Apr;16(4):376-85
pubmed: 25729921
Diabetes. 2012 Sep;61(9):2238-47
pubmed: 22596049
Nat Med. 2009 Aug;15(8):921-9
pubmed: 19633657
Hepatology. 2018 Feb;67(2):549-559
pubmed: 28892558
Nature. 2015 Mar 12;519(7542):242-6
pubmed: 25533952
Hepatology. 2018 Oct;68(4):1347-1360
pubmed: 29631332
Nat Commun. 2017 Jun 13;8:15691
pubmed: 28608850
PLoS One. 2013 Dec 18;8(12):e83481
pubmed: 24367597
J Clin Invest. 2016 Mar 1;126(3):859-64
pubmed: 26808498
Clin Immunol. 2017 Apr;177:12-17
pubmed: 26794911
Immunity. 2020 Sep 15;53(3):641-657.e14
pubmed: 32888418
Front Immunol. 2013 Dec 12;4:450
pubmed: 24376448
Metabolism. 2012 Aug;61(8):1152-61
pubmed: 22386937
Obesity (Silver Spring). 2014 Oct;22(10):2109-14
pubmed: 24962029
Int J Mol Sci. 2020 Mar 16;21(6):
pubmed: 32188134
Gastroenterology. 2016 May;150(5):1147-1159.e5
pubmed: 26874076
Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G483-G493
pubmed: 29420066
J Hepatol. 2020 Aug;73(2):394-408
pubmed: 32298766
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9
pubmed: 14676330
Immunity. 2020 Sep 15;53(3):627-640.e5
pubmed: 32562600
Immunity. 2017 Feb 21;46(2):273-286
pubmed: 28228283
Hepatology. 2018 Apr;67(4):1270-1283
pubmed: 28940700
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92
pubmed: 31605031
J Hepatol. 2020 May;72(5):885-895
pubmed: 31870950
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
J Clin Invest. 2005 May;115(5):1343-51
pubmed: 15864352
Sci Transl Med. 2019 Nov 27;11(520):
pubmed: 31776293
Front Immunol. 2016 Jan 29;7:19
pubmed: 26858722
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Cell. 2015 Jan 15;160(1-2):74-87
pubmed: 25543153
Gut. 2019 Dec;68(12):2228-2237
pubmed: 31300517
Hepatology. 2016 Jun;63(6):2032-43
pubmed: 26663351
Cell Metab. 2008 Jun;7(6):496-507
pubmed: 18522831
Front Endocrinol (Lausanne). 2019 Sep 06;10:611
pubmed: 31555219
Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110
pubmed: 26758786
Hepatology. 2014 Apr;59(4):1406-14
pubmed: 24123276
Biomaterials. 2020 Apr;237:119823
pubmed: 32044522
Liver Int. 2020 Mar;40(3):598-608
pubmed: 31758647
J Hepatol. 2019 Jun;70(6):1278-1291
pubmed: 30797053

Auteurs

Carmelo Luci (C)

Université Côte d'Azur, INSERM, C3M, Nice, France.

Manon Bourinet (M)

Université Côte d'Azur, INSERM, C3M, Nice, France.

Pierre S Leclère (PS)

Université Côte d'Azur, INSERM, C3M, Nice, France.

Rodolphe Anty (R)

Université Côte d'Azur, CHU, INSERM, C3M, Nice, France.

Philippe Gual (P)

Université Côte d'Azur, INSERM, C3M, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH